HiFiBiO Therapeutics
PrivateLast Round
Grant
Apr 16, 2024
Total Funding Raised
$179.5M
Company Overview
HiFiBiO Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Grant round in April 2024.
HiFiBiO Therapeutics is a biotechnology company that develops a single-cell analytics platform aimed at harnessing the human immune system to fight cancer and autoimmune disorders through innovative biotherapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HiFiBiO Therapeutics Comparables
Compare HiFiBiO Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioInvent International | 78% | |
| Abcuro | 74% | |
| Aureka Biotechnologies | 74% |
For institutional investors. Book with your work email.
HiFiBiO Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 16, 2024 | ||||
| Series D | Jun 14, 2021 | ||||
| Series C | Aug 28, 2019 | ||||
| Series B | May 16, 2018 | ||||
| Series A | Jan 27, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HiFiBiO Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Legend Star | Series B, Series C |
| Legend Star | Series D |
| IDG Capital | Series D, Series C |
| Nest.Bio | Series B, Series A |
| Mirae Asset | Series D |
| B Capital Group | Series D |
| LYFE Capital | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 30, 2025
Deepak Rao appointed to advise on inflammation and immunology.
- Oct 30, 2025
Peter Taylor joins the SAB to advise on inflammation and immunology.
For institutional investors. Book with your work email.
HiFiBiO Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HiFiBiO Therapeutics's valuation, stock price, and market status.
Is HiFiBiO Therapeutics a public or private company?
HiFiBiO Therapeutics is a private company.
What is the current stock price of HiFiBiO Therapeutics?
HiFiBiO Therapeutics is a private company, so its shares have no public market price. Caplight tracks HiFiBiO Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HiFiBiO Therapeutics worth (valuation)?
Valuation information for HiFiBiO Therapeutics is not publicly available.
Can I buy HiFiBiO Therapeutics stock?
HiFiBiO Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HiFiBiO Therapeutics's last funding round?
HiFiBiO Therapeutics's most recent funding round was Grant on April 16, 2024.
Who are the main investors in HiFiBiO Therapeutics?
Key investors in HiFiBiO Therapeutics include IDG Capital, Mirae Asset, LYFE Capital, Mirae Asset Financial Services, HongShan Capital Group (HSG).
Will HiFiBiO Therapeutics IPO soon?
No public IPO plans have been announced for HiFiBiO Therapeutics.
How can I track HiFiBiO Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in HiFiBiO Therapeutics's shares on secondary markets.